CA3236854A1 - Protein tyrosine phosphatase inhibitors and methods of use thereof - Google Patents
Protein tyrosine phosphatase inhibitors and methods of use thereof Download PDFInfo
- Publication number
- CA3236854A1 CA3236854A1 CA3236854A CA3236854A CA3236854A1 CA 3236854 A1 CA3236854 A1 CA 3236854A1 CA 3236854 A CA3236854 A CA 3236854A CA 3236854 A CA3236854 A CA 3236854A CA 3236854 A1 CA3236854 A1 CA 3236854A1
- Authority
- CA
- Canada
- Prior art keywords
- dihydro
- hydroxy
- fluoro
- mmol
- trione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163278339P | 2021-11-11 | 2021-11-11 | |
| US63/278,339 | 2021-11-11 | ||
| PCT/US2022/049584 WO2023086498A1 (en) | 2021-11-11 | 2022-11-10 | Protein tyrosine phosphatase inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3236854A1 true CA3236854A1 (en) | 2023-05-19 |
Family
ID=84689141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3236854A Pending CA3236854A1 (en) | 2021-11-11 | 2022-11-10 | Protein tyrosine phosphatase inhibitors and methods of use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250019374A1 (https=) |
| EP (1) | EP4430038A1 (https=) |
| JP (1) | JP2024543452A (https=) |
| CN (1) | CN118525016A (https=) |
| AU (1) | AU2022387106A1 (https=) |
| CA (1) | CA3236854A1 (https=) |
| MX (1) | MX2024005658A (https=) |
| WO (1) | WO2023086498A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20252789A1 (es) | 2023-05-24 | 2025-12-22 | Kumquat Biosciences Inc | Compuestos heterociclicos y usos de estos |
| WO2025026158A1 (zh) * | 2023-07-28 | 2025-02-06 | 杭州中美华东制药有限公司 | 具有ptpn2抑制作用的化合物及其用途 |
| WO2025242216A1 (zh) * | 2024-05-24 | 2025-11-27 | 杭州百新生物医药科技有限公司 | 吲哚啉类化合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| UA94724C2 (en) * | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
| BR112020026086A2 (pt) * | 2018-06-21 | 2021-03-23 | Calico Life Sciences Llc | inibidores da proteína tirosina fosfatase e métodos de uso destes |
| IL286373B2 (en) * | 2019-03-14 | 2026-03-01 | Calico Life Sciences Llc | Protein tyrosine phosphate inhibitor compounds and uses thereof |
| CA3162069A1 (en) * | 2019-12-18 | 2021-06-24 | Elliot P. Farney | Protein tyrosine phosphatase inhibitors and methods of use thereof |
-
2022
- 2022-11-10 WO PCT/US2022/049584 patent/WO2023086498A1/en not_active Ceased
- 2022-11-10 JP JP2024527750A patent/JP2024543452A/ja active Pending
- 2022-11-10 MX MX2024005658A patent/MX2024005658A/es unknown
- 2022-11-10 CA CA3236854A patent/CA3236854A1/en active Pending
- 2022-11-10 AU AU2022387106A patent/AU2022387106A1/en active Pending
- 2022-11-10 US US18/709,214 patent/US20250019374A1/en active Pending
- 2022-11-10 CN CN202280088273.9A patent/CN118525016A/zh active Pending
- 2022-11-10 EP EP22834767.0A patent/EP4430038A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023086498A1 (en) | 2023-05-19 |
| AU2022387106A1 (en) | 2024-05-23 |
| CN118525016A (zh) | 2024-08-20 |
| EP4430038A1 (en) | 2024-09-18 |
| US20250019374A1 (en) | 2025-01-16 |
| JP2024543452A (ja) | 2024-11-21 |
| MX2024005658A (es) | 2024-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3236854A1 (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
| EP3555096B1 (en) | Imidazopyrrolopyridine as inhibitors of the jak family of kinases | |
| EP3686196B1 (en) | Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor | |
| US20180022752A1 (en) | Fused-ring compounds, pharmaceutical composition and uses thereof | |
| KR20200010440A (ko) | 야누스 키나아제 저해제의 글루쿠로니드 프로드러그 | |
| KR20230142745A (ko) | Cdk2 억제제 및 그의 사용 방법 | |
| JP2009197010A (ja) | Ｐｐａｒアゴニスト活性を有する誘導体 | |
| AU2020405536B2 (en) | Benzimidazole derivatives | |
| WO2021161105A1 (en) | P2x3 modulators | |
| EP2834234A1 (en) | Fused cyclopentyl antagonists of ccr2 | |
| WO2023184327A1 (en) | Kinase inhibitors, preparation methods and uses thereof | |
| EP3400226A1 (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
| EP3707136B1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| TW202448866A (zh) | 治療性化合物 | |
| CA3258870A1 (en) | Substituted pyridinone compounds used as CBL-B inhibitors | |
| CA3082276C (en) | Heterocyclic compounds and their application in medicine | |
| CA3236853A1 (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
| TWI652265B (zh) | 氮雜吲哚衍生物 | |
| JP3999861B2 (ja) | 新規ピリダジン誘導体及びこれを有効成分とする医薬 | |
| OA22157A (en) | Substituted pyridinone compounds as CBL-B inhibitors. | |
| CN122003422A (zh) | 杂环pad4抑制剂 | |
| HK40055239A (en) | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | |
| NZ626745A (en) | Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof | |
| NZ626745B2 (en) | Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251031 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251031 |